Anti-Obesity Medication Market Size, Share, By Drug Type, Mechanism of Action, Distribution Channel, and Region - Trends, Analysis and Forecast till 2035

Anti-obesity medication, also known as weight loss medications, are pharmacological agents that reduce or control excess body fat. Target market is driven by the increasing cases of obesity, rising awareness of the health consequences associated with being overweight. In addition, rising R&D activities for development of anti-obesity drugs, and increasing investment in R&D sectors are another factors propelling growth of the global market.

Anti-Obesity Medication Market Report Highlights:

• The anti-obesity medication market size is expected to grow at USD 105.3 billion by 2035.
• The target market was worth USD 8.5 billion in 2024.
• Target market is expanding at a CAGR of 31.8%.
• North America held the largest share of the market in 2024.
• Asia Pacific is projected to be the fastest-growing market in the coming years.
• On the basis of drug type, the market is being dominated by the prescription drugs segment.
• Based on mechanism of action, the centrally acting drugs holds the largest anti-obesity medication market share.
• Distribution channel, the hospital pharmacies segment is leading the market.

Key Highlights:

• In November 2024, a recent study published in the JAMA Network Open, researchers evaluated changes in alcohol use among individuals enrolled in a telehealth weight management program after initiating antiobesity medication (AOM). AOMs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are effective for achieving significant weight loss. Notably, GLP-1 RAs have also been linked to reduced incidence and recurrence of alcohol use disorder, thus suggesting potential dual benefits of these medications.
• In November 2024, The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment. The new rule, which was proposed by the administration, would dramatically expand access to anti-obesity medications, such as Ozempic and Wegovy, from Novo Nordisk, and Mounjaro and Zepbound, from Eli Lilly.

Browse ∼40 market data tables and ∼38 figures through ∼183 slides and in-depth TOC on “Anti-Obesity Medication Market Size, Share, By Drug Type, Mechanism of Action, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035”

Anti-Obesity Medication Market Competitive Landscape:

The key players in the anti-obesity medication market are Novo Nordisk A/S, ELI LILLY AND COMPANY, GSK plc., Currax Pharmaceuticals LLC, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech, Inc., CHEPLAPHARM ARZNEIMITTEL GMBH, Gelesis, VIVUS LLC, Rhythm Pharmaceuticals, Inc., Lupin Ltd., Zydus Group, and BIOCON.

Segmentation:

By Drug Type:

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

By Mechanism of Action:

• Centrally Acting Drugs
• Peripherally Acting Drugs

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• Malaysia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• GCC
• Israel
• South Africa
• Rest of Middle East & Africa